Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
63
datasets available to search
ShareScore release 0.9.0
Dataset results
63 results for “cabotegravir”
Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP
ClinicalTrials.gov study NCT06145854. IPD Sharing: NO. Countries: 1. Publications: 0.
Long Acting Cabotegravir Plus Rilpivirine in People Living with HIV-1 Aged ≥ 60 Years for 24 Months.
ClinicalTrials.gov study NCT06646562. IPD Sharing: NO. Countries: 1. Publications: 0.
Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir
ClinicalTrials.gov study NCT02345707. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study
ClinicalTrials.gov study NCT07370649. IPD Sharing: NO. Countries: 1. Publications: 0.
Pharmacokinetic Interactions of ENG Subdermal Implants with Long-Acting Cabotegravir (CAB-LA) and LA Rilpivirine (RPV-LA) (CARLA)
ClinicalTrials.gov study NCT05156658. IPD Sharing: YES. Countries: 0. Publications: 0.
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
ClinicalTrials.gov study NCT05418868. IPD Sharing: YES. Countries: 1. Publications: 0.
Implementation and Delivery of Cabotegravir Long Acting Injection for PrEP in a Community Pharmacy Setting.
ClinicalTrials.gov study NCT05867212. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispersible Tablet (DT) Formulation
ClinicalTrials.gov study NCT05776108. IPD Sharing: YES. Countries: 1. Publications: 0.
Implementation of Long-acting Cabotegravir + Rilpivirine Administration Out of "HIV Units".
ClinicalTrials.gov study NCT06159894. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Real-life Study of the Use of Cabotegravir Plus Rilpivirine Long-acting in ART-experienced Pre-treated People With HIV
ClinicalTrials.gov study NCT06518408. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV
ClinicalTrials.gov study NCT06970223. IPD Sharing: YES. Countries: 1. Publications: 0.
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult Participants
ClinicalTrials.gov study NCT06033547. IPD Sharing: YES. Countries: 1. Publications: 0.
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
ClinicalTrials.gov study NCT06694805. IPD Sharing: YES. Countries: 9. Publications: 0.
The Quality of Life and Viral Control Effect of AIDS Patients After Long-acting Injection of Cabotegravir and Rilpivirine
ClinicalTrials.gov study NCT07131826. IPD Sharing: YES. Countries: 1. Publications: 0.
Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)
ClinicalTrials.gov study NCT06134362. IPD Sharing: YES. Countries: 11. Publications: 0.
Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.
ClinicalTrials.gov study NCT06273943. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults
ClinicalTrials.gov study NCT06786520. IPD Sharing: YES. Countries: 1. Publications: 0.
Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa
ClinicalTrials.gov study NCT06138600. IPD Sharing: YES. Countries: 1. Publications: 0.
Patient-Reported Outcomes in Real-life of Cabotegravir and Rilpivirine
ClinicalTrials.gov study NCT06403865. IPD Sharing: NO. Countries: 0. Publications: 0.
Satisfaction of HIV-infected Patients Treated With Cabotegravir-rilpivirine Injectable Dual Therapy
ClinicalTrials.gov study NCT05697289. IPD Sharing: Not stated. Countries: 0. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.